» Articles » PMID: 2106041

Bacillus Calmette-Guerin Versus Doxorubicin Versus Thiotepa: a Randomized Prospective Study in 202 Patients with Superficial Bladder Cancer

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 1990 Mar 1
PMID 2106041
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

We report the second interim analysis of data from a randomized prospective trial comparing the prophylactic effect of 15 courses of 50 mg. doxorubicin, 50 mg. thiotepa or 150 mg. bacillus Calmette-Guerin instilled intravesically against recurrences and progression of superficial transitional cell bladder cancer. Of 202 enrolled patients 176 currently are evaluable with a mean follow-up of 3 years (range 3 to 97 months). The number of patients with recurrences was significantly lower in the bacillus Calmette-Guerin arm (9 of 67) compared to the doxorubicin (23 of 53, p equals 0.002) and thiotepa (20 of 56, p equals 0.003) arms. The over-all recurrence index per 100 patient-months also was lower for the bacillus Calmette-Guerin versus the thiotepa and doxorubicin groups (0.53 versus 1.55 and 1.7, respectively). Bacillus Calmette-Guerin also was superior in preventing recurrences and progression of high risk tumors, that is stage T1, grade 3 or multiple growths, associated or not with carcinoma in situ. In the stage T1 category 19 of 32 (60%) tumors recurred under treatment with doxorubicin, 11 of 33 (33%) with thiotepa and 6 of 49 (12%) with bacillus Calmette-Guerin. Toxicity to intravesical bacillus Calmette-Guerin was higher compared to the other drugs but it was not limiting: bladder irritability and malaise occurred in 42% of the patients, granulomatous cystitis in 16.4% and bladder contraction in 1.4% (1 of 64). The latter complication occurred in a patient whose stage T1m grade 2 tumors had recurred 3 times, who underwent 3 transurethral bladder resections within 15 months and who had received thiotepa for 4 months after having been removed from the study 11 months after entry. Three patients in the doxorubicin group (5.6%) underwent radical cystectomy for local urothelial progression. One patient (1.8%) in the same group died of distant progression. Our preliminary results suggest that at the dose, periodicity and duration used in the study bacillus Calmette-Guerin is significantly superior to the chemotherapeutic agents doxorubicin and thiotepa for the prophylaxis of recurrence and retardation of progression in superficial transitional cell bladder tumors.

Citing Articles

Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer.

Ostrowski D, Chelluri R, Herzig M, Xia L, Cortese B, Roberson D Cancers (Basel). 2023; 15(14).

PMID: 37509407 PMC: 10377836. DOI: 10.3390/cancers15143746.


Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.

Del Giudice F, Asero V, Bologna E, Scornajenghi C, Carino D, Dolci V Cancers (Basel). 2023; 15(7).

PMID: 37046598 PMC: 10093360. DOI: 10.3390/cancers15071937.


Bacterial-Mediated Tumor Therapy: Old Treatment in a New Context.

Liu Y, Niu L, Li N, Wang Y, Liu M, Su X Adv Sci (Weinh). 2023; 10(12):e2205641.

PMID: 36908053 PMC: 10131876. DOI: 10.1002/advs.202205641.


Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma.

Doroud D, Hozouri H Iran Biomed J. 2022; 26(5):340-9.

PMID: 36369747 PMC: 9763876. DOI: 10.52547/ibj.3676.


Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).

Jin Y, Zeng X, Liu T, Bai Z, Dou Z, Ding D Mil Med Res. 2022; 9(1):44.

PMID: 35978389 PMC: 9382792. DOI: 10.1186/s40779-022-00406-y.